Amphastar Pharmaceuticals (AMPH) Rating Increased to Hold at BidaskClub

Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other research analysts have also recently commented on the company. Piper Jaffray Companies reiterated a “buy” rating and issued a $26.00 price target on shares of Amphastar Pharmaceuticals in a research note on Tuesday, January 30th. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $22.00 target price for the company in a research report on Tuesday, January 23rd. Needham & Company LLC raised their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a research report on Friday, December 1st. BMO Capital Markets raised their target price on Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the stock a “market perform” rating in a research report on Friday, November 10th. Finally, Raymond James Financial lowered Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 target price for the company. in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $20.83.

Shares of Amphastar Pharmaceuticals (NASDAQ AMPH) traded up $0.55 on Friday, hitting $18.40. The stock had a trading volume of 269,071 shares, compared to its average volume of 157,376. Amphastar Pharmaceuticals has a one year low of $12.05 and a one year high of $19.95. The company has a market cap of $820.67, a PE ratio of 119.00, a price-to-earnings-growth ratio of 1.25 and a beta of 1.51. The company has a quick ratio of 1.86, a current ratio of 3.08 and a debt-to-equity ratio of 0.13.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 EPS for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The company had revenue of $57.90 million during the quarter, compared to analysts’ expectations of $57.23 million. During the same period in the prior year, the company earned $0.14 EPS. Amphastar Pharmaceuticals’s revenue was down 9.8% compared to the same quarter last year. research analysts anticipate that Amphastar Pharmaceuticals will post -0.04 earnings per share for the current fiscal year.

In related news, Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $18.04, for a total transaction of $141,830.48. Following the completion of the transaction, the director now directly owns 31,978 shares of the company’s stock, valued at approximately $576,883.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO William J. Peters sold 6,226 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $19.67, for a total value of $122,465.42. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 75,443 shares of company stock valued at $1,434,441. 11.10% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. Rhumbline Advisers grew its holdings in Amphastar Pharmaceuticals by 13.3% during the 4th quarter. Rhumbline Advisers now owns 80,688 shares of the company’s stock worth $1,552,000 after acquiring an additional 9,455 shares during the period. Arizona State Retirement System grew its holdings in Amphastar Pharmaceuticals by 221.6% during the 4th quarter. Arizona State Retirement System now owns 59,499 shares of the company’s stock worth $1,145,000 after acquiring an additional 40,999 shares during the period. Wells Fargo & Company MN grew its holdings in Amphastar Pharmaceuticals by 156.1% during the 4th quarter. Wells Fargo & Company MN now owns 176,323 shares of the company’s stock worth $3,392,000 after acquiring an additional 107,486 shares during the period. Swiss National Bank grew its holdings in Amphastar Pharmaceuticals by 11.8% during the 4th quarter. Swiss National Bank now owns 66,400 shares of the company’s stock worth $1,278,000 after acquiring an additional 7,000 shares during the period. Finally, Teacher Retirement System of Texas acquired a new stake in Amphastar Pharmaceuticals during the 4th quarter worth about $242,000. Hedge funds and other institutional investors own 43.94% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Amphastar Pharmaceuticals (AMPH) Rating Increased to Hold at BidaskClub” was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/10/amphastar-pharmaceuticals-amph-rating-increased-to-hold-at-bidaskclub.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply